Increased expression of the INK4a/ARF locus in polycythemia vera

Blood

Volumn 97, Issue 11, 2001, Pages 3424-3432

  Dai, Chunhua ^a,b   Krantz, Sanford B ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; RETINOBLASTOMA PROTEIN; RNA;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMING CELL; ERYTHROID CELL; EXON; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE LOCUS; GRANULOCYTE; HEMATOPOIESIS; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

EID: 0035383807     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3424     Document Type: Article

References (51)

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinman L. Polycythemia vera: stem cell and probable clonal origin of the disease. N Engl J Med.1976;295:913-916.
2. Green AR. Pathogenesis of polycythemia vera. Lancet. 1996;347:844-845.
3. Heimpel H. The present state of pathophysiology and therapeutic trials in polycythemia vera. Int J Hematol.1996;64:153-165.
4. Hinsheiwood S, Bench AJ, Green AR. Pathogenesis of polycythemia vera. Blood Rev. 1997;11: 224-232.
5. Michiels JJ, Barbui T, Finazzi G, et al. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leuk Lymph. 2000;36:239-258.
6. Zanjani, ED, Lutton JD, Hoffman R, Wasserman LR. Erythroid colony formation by polycythemia vera bone marrow in vitro. J Clin Invest. 1977;59: 841-848.
7. Fisher MJ, Prchal JF, Prchal JT, D'Andrea AD. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood. 1994;84:1982-1991.
8. Cotes PM, Dore CJ, Liu Yin JA, Messinezy M, Pearson TC, Reid C. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N Engl J Med. 1986;315:283- 287.
9. Dai CH, Krantz SB, Means RT, Horn WT, Gilbert HS. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to inteleukin-3. J Clin Invest. 1991;87:391-396.
10. Dai CH, Krantz SB, Dessypris EN, Means RT Jr, Horn ST, Gilbert HS. Polycythemia vera I: hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood. 1992;80:891-899.
11. Dai CH, Krantz SB, Green WF, Gilbert HS. Poly-cythemia vera III: burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol. 1994;86:12- 21.
12. Correa PN, Eskinazi D, Axeirad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulinlike growth factor-1 in vitro: studies in an improved serum-free medium. Blood. 1994;83:99-112.
13. Mizra AM, Correa PN, Axelrad AA. Increased basal and induced tyrosine phosphorylation of the insulinlike growth factor I receptor β subunit in circulating mononuclear cells of patients with polycythemia vera. Blood. 1995;86:877-882.
14. Mizra AM, Ezzat S, Axelrad AA. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Blood. 1997;89: 1862-1869.
15. Means RT Jr, Krantz SB, Sawyer ST, Gilbert HS. Erythropoietin receptors in polycythemia vera. J Clin Invest. 1989;84:1340-1344.
16. Dai CH, Krantz SB, Koury ST, Kollar K. Polycythemia vera IV: specific binding of stem cell factor to normal and polycythemia vera highly purified erythroid progenitor cells. Br J Haematol. 1994; 88:497-505.
17. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna J. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338:564-571.
18. Dai CH, Krantz SB, Saywer ST. Polycythemia vera V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: a possible defect of phosphatase activity in polycythemia vera. Blood. 1997;89:3574-3581.
19. Sui X, Krantz SB, Zhao Z. Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells. Blood. 1997;90;651-657.
20. Asimakopoulos FA, Hinshelwood S, Gilbert JGR, et al. The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene. 1997; 14:1215-1222.
21. Wickrema A, Chen F, Namin F, et al. Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol. 1999;27:1124-1132.
22. Morgan DO. Cell cycle control in normal and neoplastic cells. Curr Opin Genet Dev. 1992;2:33-37.
23. Reddy GP. Cell cycle: regulatory events in G1-S transition of mammalian cells. J Cell Biochem. 1994;54:379-386.
24. Vogt PK, Reed SI. Cyclin Dependent Kinase (CDK) Inhibitors. Current Topics in Microbiology and Immunology. Vol 272. New York, NY: Springer; 1998:43-148.
25. Graña X, Reddy EP Cell cycle control in mammalian cells; role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995;11:211-219.
26. Sharpless NE, DePinho RA. The INK4a/ARF locus and its two gene products. Curr Opin Genet and Dev. 1999;9:22-30.
27. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366: 704-707.
28. Seranno M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis. 2000;21:865-869.
29. ARF involvement in familiar melanoma kindreds. J Invest Dermatol. 1998;111:1202-1206.
30. Suzuki H, Fujioka Y, Nagashima K. Cyclin D1 gene amplification and p16 gene deletion in patients with esophageal carcinosarcoma. Diag Molec Pathol. 1998;7:253-259.
31. INK4A gene alterations in hepatocellular carcinoma. Oncogene. 1999;18:789-795.
32. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95: 11891-11896.
33. INK4a/p16α and p19ARF/P16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene. 1998;17:2779-2785.
34. Herranz M, Urioste M, Santos J, et al. Analysis of the INK4a/ARF locus in non-Hodgkin's lymphomas using two new internal microsatellite markers. Leukemia. 1999;13:808-810.
35. ARF in hematological malignancies. Leukemia. 1999;13:1760-1769.
36. INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84:4038-4044.
37. Quesnel B, Preudhomme C, Philippe N, et al. P16 gene homozygous deletions in acute lymphoblastic leukemia. Blood. 1995;85:657-668.
38. Quelle DE, Zindy F, Ashmun RA, and Sherr CJ. Alternative reading frames of the Ink4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995; 83:993-1000.
39. Sawada K, Krantz SB, Kans JS, et al. Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin. J Clin Invest. 1987;80:357-366.
40. Michiels J, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the thrombocythemia vera study group. Sem Thromb Hemostas. 1997;23: 339-347.
41. Dai CH, Price JO, Brunner T, Krantz SB. Fas Ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon γ to produce erythroid cell apoptosis. Blood. 1998;91:1235-1242.
42. Ross JS. DNA ploidy and Cell Cycle Analysis in Pathology. Vol 1. New York, NY: Igaku-Shoin Medical Pubs, 1996.
43. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res. 1995;55:2988-2994.
44. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene. 1999;18:5311-5317.
45. + cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Pro Natl Acad Sci U S A. 2000;97:10538-10543.
46. Weber JD, Taylor LB, Roussel MF, Sherr CJ, BarSagi D. Nucleolar Art sequesters Mdm2 and activates p53. Nature Cell Biol. 1999;1:20-26.
47. Zhang Y, Ziong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: Arf-Ink4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92:725-734.
48. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995;269:1281-1284.
49. INK4a binding domain of CDK4 in familial melanoma. Nature Genetics. 1996; 12:97-99.
50. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994; 54:6078-6082.
51. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO. 1998;17:5001-5014.